New hope for rare blood cancer: drug cocktail targets stubborn LCH
NCT ID NCT07204041
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 32 times
Summary
This study tests a three-drug combination (selinexor, thalidomide, and dexamethasone) in 40 adults with a rare blood disorder called Langerhans cell histiocytosis (LCH) that has not responded to or has returned after prior treatment. The goal is to see if the regimen can control the disease and improve survival. Participants will receive the drugs and be monitored for side effects and disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing,
Beijing, China
Conditions
Explore the condition pages connected to this study.